Prospective evaluation of the clinical utility of different methods for the detection of human cytomegalovirus disease after liver transplantation

American Journal of Transplantation

Volumn 4, Issue 8, 2004, Pages 1331-1337

  Seehofer, Daniel ^a   Meisel, Helga ^a   Rayes, Nada ^a   Stein, Angela ^a   Langrehr, Jan M ^a   Settmacher, Utz ^a   Neuhaus, Peter ^a  

^a HUMBOLDT UNIVERSITY   (Germany)

Author keywords

CMV infection; Liver transplantation; pp65 antigenemia; pp67 mRNA; Quantitative CMV PCR

Indexed keywords

ANTIGEN PP67; BASILIXIMAB; CYTOMEGALOVIRUS ANTIBODY; CYTOMEGALOVIRUS ANTIGEN PP65; GANCICLOVIR; MESSENGER RNA; METHYLPREDNISOLONE; OKT 3; ORTHOCLONE; UNCLASSIFIED DRUG; VIRUS ANTIGEN; VIRUS DNA;

ADULT; ARTICLE; COST BENEFIT ANALYSIS; CYTOMEGALOVIRUS INFECTION; DIAGNOSTIC ACCURACY; DNA DETERMINATION; FEMALE; HUMAN; HUMAN CYTOMEGALOVIRUS; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; POSTOPERATIVE INFECTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; VIRUS DETECTION; VIRUS RESISTANCE;

ANTIGENS, VIRAL; ANTIVIRAL AGENTS; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; DNA, VIRAL; DRUG RESISTANCE; FEMALE; GANCICLOVIR; HEMATOLOGIC TESTS; HUMANS; LIVER TRANSPLANTATION; MALE; PHOSPHOPROTEINS; POLYMERASE CHAIN REACTION; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; RNA; RNA, MESSENGER; SENSITIVITY AND SPECIFICITY; TIME FACTORS; VIRAL MATRIX PROTEINS; VIREMIA;

EID: 3542991489     PISSN: 16006135     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1600-6143.2004.00510.x     Document Type: Article

References (29)

1. Seehofer D, Rayes N, Steinmüller T et al. Minimal impact of CMV-infection on long term survival after liver transplantation. Transplant Proc 2002; 34: 2272-2273.
2. Singh N, Paterson DL, Gayowski T, Wagener MM, Marino IR. Cytomegalovirus antigenemia directed pre-emptive prophylaxis with oral versus i.v. ganciclovir for the prevention of cytomegalovirus disease in liver transplant recipients. Transplantation 2000; 70: 717-722.
3. Paya CV, Wilson JA, Espy MJ et al. Preemptive use of oral ganciclovir to prevent cytomegalovirus infection in liver transplant patients: a randomized, placebo-controlled trial. J Infect Dis 2002; 185: 854-860.
4. Künzle N, Petignat C, Francioli P et al. Preemptive treatment approach to cytomegalovirus (CMV) infection in solid organ transplant patients: relationship between compliance with the guidelines and prevention of CMV morbidity. Transpl Infect Dis 2000; 2: 118-126.
5. Rayes N, Seehofer D, Schmidt CA et al. Prospective randomised trial to assess the value of preemptive oral therapy for CMV infection following liver transplantation. Transplantation 2001; 72: 881-885.
6. Rayes N, Seehofer D, Schmidt CA et al. Is preemptive therapy for CMV infection following liver transplantation superior to symptom-triggered treatment? Transplant Proc 2001; 33: 1804.
7. van den Berg AP, Klompmaker IJ, Haagsma EB et al. Antigenemia in the diagnosis and monitoring of active cytomegalovirus infection after liver transplantation. J Infect Dis 1991; 164: 265-270.
8. Storch GA, Buller RS, Bailey TC et al. Comparison of PCR and pp65 antigenemia assay with quantitative shell vial culture for detection of cytomegalovirus in blood leukocytes from solid-organ transplant recipients. J Clin Microbiol 1994; 32: 997-1003.
9. Emery VC, Sabin CA, Cope AV, Gor D, Hassan-Walker AF, Griffiths PD. Application of viral-load kinetics to identify patients who develop cytomegalovirus disease after transplantation. Lancet 2000; 355: 2032-2036.
10. Humar A, Gregson D, Caliendo AM et al. Clinical utility of quantitative cytomegalovirus viral load determination for predicting cytomegalovirus disease in liver transplant recipients. Transplantation 1999; 68: 1305-1311.
11. Blok MJ, Goossens VJ, Vanherle SJV et al. Diagnostic value of monitoring human cytomegalovirus late pp67 mRNA expression in renal allograft recipients by nucleic acid sequence based amplification. J Clin Microbiol 1998; 36: 1341-1346.
12. Patel R, Smith TF, Espy M et al. Detection of cytomegalovirus DNA in sera of liver transplant recipients. J Clin Microbiol 1994; 32: 1431-1434.
13. Patel R, Smith TF, Espy M et al. A prospective comparison of molecular diagnostic techniques for the early detection of cytomegalovirus in liver transplant recipients. J Infect Dis 1994; 171: 1010-1014.
14. Fox JC, Kidd IM, Griffiths PD, Sweny P, Emery VC. Longitudinal analysis of cytomegalovirus load in renal transplant recipients using a quantitative polymerase chain reaction: correlation with disease. J Gen Virol 1995; 76: 303-319.
15. Bitsch A, Kirchner H, Dupke R, Bein G. Cytomegalovirus transcripts in peripheral blood leukocytes of actively infected transplant patients by reverse transcriptase polymerase chain reaction. J Infect Dis 1993; 167: 740-743.
16. Gerna G, Baldanti F, Middeldorp JM et al. Clinical significance of human cytomegalovirus pp67 late transcript in heart, lung, and bone marrow transplant recipients as determined by nucleic acid sequence-based amplification. J Clin Microbiol 1993; 37: 902-911.
17. Ljungman P, Griffiths P, Paya C. Definitions of cytomegalovirus infection and disease in transplant recipients. Clin Infect Dis 2002; 34: 1094-1097.
18. Singhal S, Khan OA, Bramble RA, Mutimer D. Cytomegalovirus disease following liver transplantation: an analysis of prophylaxis strategies. Hepatology 2003; 47: 104-109.
19. Stratta RJ, Shaeffer MS, Markin RS et al. Cytomegalovirus infection and disease after liver transplantation. Dig Dis Sci 1992; 37: 673-688.
20. Moreso F, Seron D, Morales JM et al. Incidence of leukopenia and cytomegalovirus disease in kidney transplants treated with mycophenolate mofetil combined with low cyclosporine and steroid doses. Clin Transplant 1998; 12: 198-205.
21. de Maar EF, Verschuuren EAM, Homan vd Heide JJ et al. Effects of changing immunosuppressive regimen on the incidence, duration and viral load of cytomegalovirus infection in renal transplantation: a single center report. Transpl Infect Dis 2002; 4: 17-24.
22. Badley AD, Seaberg EC, Porayko MK et al. Prophylaxis of cytomegalovirus infection in liver transplantation. Transplantation 1997; 64: 66-73.
23. Winston DJ, Warin D, Shaked A, Busutil RW. Randomized trial of ganciclovir and high dose aciclovir for long term cytomegalovirus prophylaxis in liver transplant recipients. Lancet 1995; 346: 69-74.
24. Daly JS, Kopasz A, Anandakrishnan R et al. Preemptive strategy for ganciclovir administration against cytomegalovirus in liver transplantation recipients. Am J Transplant 2002; 2: 955-958.
25. Singhal S, Khan OA, Bramble RA, Mutimer DJ. Cytomegalovirus disease following liver transplantation: an analysis of prophylactic strategies. J Infect 2003; 47: 104-109.
26. Limaye AP, Corey L, Koelle DM, Davis CL, Boeckh M. Emergence of ganciclovir resistant cytomegalovirus disease among recipients of solid organ transplants. Lancet 2000; 356: 645-649.
27. Mendez J, Espy M, Smith TF, Wilson J, Wiesner R, Paya CV. Clinical significance of viral load in the diagnosis of cytomegalovirus disease after liver transplantation. Transplantation 1998; 65: 1477-1481.
28. von Müller L, Hampl W, Hinz J et al. High variability between results of different in-house tests for cytomegalovirus (CMV) monitoring and a standardized quantitative plasma PCR assay. J Clin Microbiol 2002; 40: 2285-2287.
29. Kusne S, Grossi P, Irish W et al. Cytomegalovirus pp65 antigenemia monitoring as a guide for preemptive therapy: a cost effective strategy for prevention of cytomagalovirus disease in adult liver transplant recipients. Transplantation 1999; 68: 1125-1131.